Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
出版年份 2022 全文链接
标题
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
作者
关键词
-
出版物
Lancet Haematology
Volume 9, Issue 2, Pages e98-e110
出版商
Elsevier BV
发表日期
2022-01-13
DOI
10.1016/s2352-3026(21)00381-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
- (2021) Juho J. Miettinen et al. Cancers
- OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma
- (2020) Fredrik Schjesvold et al. Future Oncology
- Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
- (2020) Paul G Richardson et al. Lancet Haematology
- Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2020) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- DPP8 is a novel therapeutic target for multiple myeloma
- (2019) Tsutomu Sato et al. Scientific Reports
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Melflufen - a peptidase-potentiated alkylating agent in clinical trials
- (2017) Malin Wickström et al. Oncotarget
- A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
- (2016) Arghya Ray et al. BRITISH JOURNAL OF HAEMATOLOGY
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
- (2010) Malin Wickström et al. BIOCHEMICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search